NasdaqGS:IART

Stock Analysis Report

Integra LifeSciences Holdings

Executive Summary

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.

Snowflake

Fundamentals

Acceptable track record with moderate growth potential.


Similar Companies

Share Price & News

How has Integra LifeSciences Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.8%

IART

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

-1.8%

IART

11.9%

US Medical Equipment

5.9%

US Market

Return vs Industry: IART underperformed the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: IART underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

IARTIndustryMarket
7 Day1.8%-0.003%1.3%
30 Day-1.4%-3.0%-1.9%
90 Day13.7%-0.6%-1.8%
1 Year-1.8%-1.8%12.8%11.9%8.3%5.9%
3 Year50.0%50.0%69.6%64.5%45.6%36.2%
5 Year172.8%146.6%129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is Integra LifeSciences Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Integra LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?

11.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: IART ($60.57) is trading below our estimate of fair value ($68.47)

Significantly Undervalued: IART is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: IART is poor value based on its PE Ratio (51.2x) compared to the Medical Equipment industry average (40.1x).

PE vs Market: IART is poor value based on its PE Ratio (51.2x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

Low PEG Ratio: IART is poor value based on its PEG Ratio (1.8x)


Price to Book Ratio

PB vs Industry: IART is good value based on its PB Ratio (3.6x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

27.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IART's forecast earnings growth (27.8% per year) is above the savings rate (2.7%).

Earnings vs Market: IART's earnings (27.8% per year) are forecast to grow faster than the US market (14.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: IART's revenue (5% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: IART's revenue (5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: IART's Return on Equity is forecast to be low in 3 years time (15.2%).


Next Steps

Past Performance

How has Integra LifeSciences Holdings performed over the past 5 years?

29.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IART has become profitable over the past 5 years, growing earnings by 29.6% per year.

Accelerating Growth: IART's earnings growth over the past year (44.4%) exceeds its 5-year average (29.6% per year).

Earnings vs Industry: IART earnings growth over the past year (44.4%) exceeded the Medical Equipment industry 28.2%.


Return on Equity

High ROE: IART's Return on Equity (7.1%) is considered low.


Return on Assets

ROA vs Industry: IART's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: IART has not improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Integra LifeSciences Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IART's short term assets ($868.7M) exceeds its short term liabilities ($315.1M)

Long Term Liabilities: IART's short term assets (868.7M) do not cover its long term liabilities (1.6B)


Debt to Equity History and Analysis

Debt Level: IART's debt to equity ratio (98.2%) is considered high

Reducing Debt: IART's debt to equity ratio has increased from 91.8% to 98.2% over the past 5 years.

Debt Coverage: IART's debt is not well covered by operating cash flow (14.3%).

Interest Coverage: IART's interest payments on its debt are well covered by EBIT (5.3x coverage).


Balance Sheet

Inventory Level: IART has a high level of physical assets or inventory.

Debt Coverage by Assets: IART's debt is not covered by short term assets (assets are 0.6x debt).


Next Steps

Dividend

What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IART's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Integra LifeSciences Holdings's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Pete Arduini (54yo)

7.8yrs

Tenure

US$7,647,812

Compensation

Mr. Peter J. Arduini, also known as Pete, has been Chief Executive Officer and President at Derma Sciences, Inc. since February 2017. Mr. Arduini has been the Chief Executive Officer of Integra LifeScience ...


CEO Compensation Analysis

Compensation vs. Market: Pete's total compensation ($USD7.65M) is about average for companies of similar size in the US market ($USD6.81M).

Compensation vs Earnings: Pete's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.8yrs

Average Tenure

54yo

Average Age

Experienced Management: IART's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

7.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: IART's board of directors are considered experienced (7.2 years average tenure).


Insider Trading

Insider Buying: IART insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$31,704,14020 Sep 19
Tru St Partnership LP
EntityCompany
Shares520,000
Max PriceUS$60.97
SellUS$57,98413 Sep 19
Joseph Vinhais
EntityIndividual
Shares910
Max PriceUS$63.72
SellUS$429,95826 Aug 19
John Mooradian
EntityIndividual
Shares7,000
Max PriceUS$61.42
SellUS$4,941,60026 Aug 19
Tru St Partnership LP
EntityCompany
Shares80,000
Max PriceUS$61.77
SellUS$252,24620 Aug 19
Raymond Murphy
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,136
Max PriceUS$60.99
SellUS$74,69331 Jul 19
Jeffrey Mosebrook
EntityIndividual
Role
Chief Accounting Officer
VP, Principal Accounting Officer & Corporate Controller
Shares1,179
Max PriceUS$63.35
SellUS$149,94030 Jul 19
Lisa Evoli
EntityIndividual
Shares2,380
Max PriceUS$63.00
SellUS$72,16718 Mar 19
Lisa Evoli
EntityIndividual
Shares1,291
Max PriceUS$55.90
BuyUS$108,39918 Mar 19
Rhonda Ballintyn
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,933
Max PriceUS$56.08
BuyUS$199,68306 Nov 18
Barbara Hill
EntityIndividual
Role
Lead Director
Presiding Director
Shares3,705
Max PriceUS$53.90
SellUS$2,949,51918 Oct 18
Provco Leasing Corporation
EntityCompany
Shares46,676
Max PriceUS$63.22

Ownership Breakdown


Management Team

  • Richard Caruso (76yo)

    Founder and Chairman Emeritus

    • Tenure: 2.4yrs
    • Compensation: US$37.50k
  • Dan Reuvers (56yo)

    Corporate VP & President of Specialty Surgical Solutions

    • Tenure: 2.8yrs
    • Compensation: US$1.82m
  • Pete Arduini (54yo)

    President

    • Tenure: 7.8yrs
    • Compensation: US$7.65m
  • Eric Schwartz (50yo)

    Corporate VP

    • Tenure: 0.9yrs
    • Compensation: US$1.14m
  • Glenn Coleman (51yo)

    COO & Corporate VP of International

    • Tenure: 0.3yrs
    • Compensation: US$2.29m
  • Ken Burhop (65yo)

    Corporate VP & Chief Scientific Officer

    • Tenure: 5.7yrs
  • Bob Davis (60yo)

    Corporate VP and President of Orthopedics & Tissue Technologies

    • Tenure: 6.8yrs
    • Compensation: US$1.37m
  • William Compton

    Chief Information Officer & Senior VP

    • Tenure: 0yrs
  • Carrie Anderson (50yo)

    Corporate VP

    • Tenure: 0.3yrs
  • Jeffrey Mosebrook (43yo)

    VP, Principal Accounting Officer & Corporate Controller

    • Tenure: 2yrs

Board Members

  • Ray Murphy (71yo)

    Director

    • Tenure: 10.5yrs
    • Compensation: US$282.58k
  • Richard Caruso (76yo)

    Founder and Chairman Emeritus

    • Tenure: 2.4yrs
    • Compensation: US$37.50k
  • Donald Morel (61yo)

    Director

    • Tenure: 6.2yrs
    • Compensation: US$270.03k
  • Chris Schade (58yo)

    Director

    • Tenure: 13.8yrs
    • Compensation: US$280.03k
  • Stuart Essig (57yo)

    Chairman

    • Tenure: 7.8yrs
    • Compensation: US$370.07k
  • Barbara Hill (67yo)

    Presiding Director

    • Tenure: 1.1yrs
    • Compensation: US$275.14k
  • Keith N. Bradley (74yo)

    Director

    • Tenure: 27.8yrs
    • Compensation: US$275.08k
  • Rhonda Ballintyn (62yo)

    Director

    • Tenure: 0.8yrs
  • Pete Arduini (54yo)

    President

    • Tenure: 7.8yrs
    • Compensation: US$7.65m
  • Lloyd Howell (52yo)

    Director

    • Tenure: 6.6yrs
    • Compensation: US$265.08k

Company Information

Integra LifeSciences Holdings Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Integra LifeSciences Holdings Corporation
  • Ticker: IART
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$5.181b
  • Shares outstanding: 85.53m
  • Website: https://www.integralife.com

Number of Employees


Location

  • Integra LifeSciences Holdings Corporation
  • 311 Enterprise Drive
  • Plainsboro
  • New Jersey
  • 8536
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IARTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 1995
IL3DB (Deutsche Boerse AG)YesCommon StockDEEURAug 1995

Biography

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 23:36
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.